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ABSTRACT
Background: The management of Henoch-Schönlein purpura nephritis 
(HSPN) in childhood is controversial. Adjuvant therapies such as immunoglobulin, 
anticoagulants, and vitamins have been used with conventional treatments despite a 
lack of evidence of their efficacy.
Objective: The aim of this study was to review the scientific literature regard-
ing adjuvant treatments administered with conventional drugs in the treatment of 
childhood HSPN.
Methods: Published articles were identified from the MEDLINE and EMBASE 
databases (1988–December 2008; key words: Henoch-Schönlein nephritis and Henoch-
Schönlein purpura). The search was limited to published English-language studies on 
therapeutic options for HSPN in children.
Results: A total of 12 studies were identified and included in this review; most 
(n = 8) were case series or retrospective studies. Studies of conventional therapy com-
bined with adjuvant treatment should be interpreted with caution. In particular, fac-
tor XIII administration was reported to improve kidney symptoms in 1 study. Based 
on the results from 9 studies, no convincing evidence on intravenous immunoglobu-
lin, urokinase, or anticoagulants was identified. No substantial information was avail-
able on the benefit of antiplatelet agents or heparin in treating HSPN. Integrating 
treatment with vitamin E was not recommended based on the results from 1 random-
ized controlled trial. Fish oil was reported to be effective in 1 case series.
Conclusions: Studies concerning the treatment of HSPN in children with 
adjuvant therapies were retrospective and recommendations were drawn from level IV 
evidence. One randomized controlled trial on the use of tocopherol as adjuvant treat-
ment was identified; however, no clinical utility was reported. At present, there is no 
strong evidence supporting benefits with the use of adjuvant treatments. (Curr Ther 
Res Clin Exp. 2009;70:254–265) © 2009 Excerpta Medica Inc.
Key words: glomerulonephritis, Henoch-Schönlein purpura, Henoch-Schönlein 
purpura nephritis, adjuvant therapies, evidence-based approach.
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INTRODUCTION
Henoch-Schönlein purpura (HSP) is a systemic vasculitic disease in children and ado-
lescents characterized by the triad of palpable purpura, abdominal pain, and arthritis.1 
The annual incidence of HSP nephritis (HSPN) is ~2 cases per million children.2 
Renal involvement in HSP varies in prevalence and severity. Clinical expression of 
HSPN ranges from transient, isolated, microscopic hematuria to nephrotic syndrome,3 
and from rapidly progressive glomerulonephritis to kidney failure.4,5 Renal involve-
ment typically develops within 3 months of disease onset.6 Although renal changes 
have been reported in 17% of HSP patients in a US study, <2% of patients developed 
a serious renal complication.7,8 Such complications (eg, chronic glomerular nephropa-
thy or persistent or increased fibrinogen deposits in the kidney) might not be observed 
until years after diagnosis.9
The management of HSPN in childhood is controversial. Conventional drugs (eg, 
corticosteroids, cyclosporine A [CSA], cyclophosphamide) and plasmapheresis have 
been reported to have variable success in altering long-term renal outcome, but their 
use is not adequately guided by evidence obtained from properly designed, random-
ized, placebo-controlled trials with outcome markers related to the progression of 
end-stage renal disease (level I evidence).10 No properly designed studies of HSPN 
treatment in pediatric patients found corticosteroids plus adjuvant therapy to be ef-
fective.11 A systematic review of 4 randomized controlled trials (RCTs) found no 
significant difference in the risk for persistent kidney disease at 6 and 12 months with 
prednisone administered at presentation compared with placebo.12 In children with 
severe renal disease, treatment with cyclophosphamide compared with supportive 
treatment, and treatment with CSA compared with methylprednisolone, had no sig-
nificant difference in the risk for persistent renal disease. Thus, data from randomized 
controlled trials of conventional treatment used to improve renal outcomes in children 
with HSPN are limited. 
Adjuvant therapies, such as immunoglobulin (Ig), anticoagulants, enzymes, and vi-
tamins, have been used in combination with conventional treatments, although there is 
no clear evidence of their efficacy. Based on clinical observation, adjuvant treatment has 
been used to treat specific conditions associated with HSPN. In particular, treatment 
with intravenous Ig (IVIg) has been associated with the downregulation of proinflam-
matory cytokines. The enzyme urokinase has been used with the aim of preventing 
mesangial proliferation observed in HSPN during childhood.13,14 However, because the 
coagulation factors should be altered in the serum of children with HSP, substitution 
therapy with coagulation factors has also been considered.15 In particular, factor XIII 
activity is decreased in children with severe forms of HSP. Decreased factor XIII activity, 
together with persistent purpura, appears to increase the risk for renal involvement in 
children aged >7 years with HSP.16,17 Furthermore, because both oxidative damage and 
lipid peroxidation may play an important role in the pathogenesis of HSPN, antioxi-
dants such as vitamin E have also been studied as adjuvant treatment.18 The Ω-3 poly-
unsaturated fatty acids (fish oil) might be effective in attenuating inflammatory re-
sponses.19 Thus, the renoprotective effects of fish oil in HSPN might be the result of the 
mitigation of glomerular or tubulointerstitial inflammation.
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In this article, we reviewed the scientific literature concerning the adjuvant treat-
ments administered with conventional drugs in the treatment of childhood HSPN.
MATERIALS AND METHODS
Sources
Articles from the literature were searched on the MEDLINE and EMBASE data-
bases (1988–December 2008; key words: Henoch-Schönlein nephritis and Henoch-Schönlein 
purpura). The search was limited to published studies that focused on therapeutic 
options for children. Only English-language publications were included.
Study Selection
Conventional therapies were defined as drugs or procedures (eg, plasmapheresis) that 
act as immune modulators. Adjuvant therapies were defined as any secondary treatment 
used in addition to the primary treatment that increases the likelihood of cure (eg, 
IVIg, anticoagulants, enzymes). For this review, we included all studies of Ig, antico-
agulants, enzymes, and vitamins. Because the renal implications, clinical monitoring, 
and conventional treatment modalities differ in terms of outcome measures for moder-
ate urinary abnormalities and severe HSPN, their results were analyzed separately.
To assess the efficacy of the treatment, we adopted the scheme described by Shekelle 
et al,20 in which the level of evidence was classified in descending order, as follows: Ia = 
evidence from a meta-analysis of RCTs; Ib = evidence from ≥1 RCT; IIa = evidence from 
≥1 controlled study without randomization; IIb = evidence from ≥1 other type of quasi-
experimental study; III = evidence from nonexperimental descriptive studies, such as 
comparative, correlation, or case–control studies; and IV = evidence from expert com-
mittee reports or opinions, or from clinical experience of respected authorities or both. 
These levels of evidence were used to determine the strength of the recommendation for ad-
juvant treatment. The recommendations were graded as follows20: A (levels Ia and Ib), 
which required ≥1 RCT of good quality addressing the specific recommendations; 
B (levels IIa, IIb, and III), which required availability of well-conducted clinical studies 
but no clinical trials on the topic of the recommendations; and C (level IV), which 
presented evidence from expert committee reports or opinions or clinical experience of 
respected authorities, but indicated an absence of directly applicable studies.
Studies were categorized according to 2 clinical patterns of renal involvement in 
HSPN10,11: the moderate urinary abnormalities pattern, in cases of isolated proteinuria, 
and the severe HSPN pattern, characterized by crescent formations at renal biopsy. The 
glomerular changes were graded according to the classification of HSPN by the Inter-
national Study of Kidney Disease in Children (ISKDC).21 
The authors, working independently, used data extraction forms to extract the data, 
perform data synthesis, and evaluate the design of the studies. 
RESULTS
A total of 12 studies were identified, 6 describing moderate urinary abnormali-
ties,12,17–19,22,23 and 6 describing severe HSPN.5,13,24–27 Most (n = 8) were case series 
or retrospective studies.
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Moderate Urinary Abnormalities
Table I shows adjuvant treatment in children with isolated proteinuria with or 
without nephrotic syndrome. Six studies matched the selection criteria.12,17–19,22,23
Intravenous Immunoglobulin
Two studies reported the use of IVIg.22,23 In a prospective, nonrandomized case 
series of 14 patients, Rostoker et al22 examined the usefulness of 3-month treatment 
with IVIg 2 g/kg/mo followed by IM Ig 0.35 mL/kg twice a month for 
8 months in treating nephritis with significant proteinuria. Both the severity of pro-
teinuria and the acuity index improved in the majority (78%) of these patients with 
stage III renal histology and normal renal function. In a retrospective, uncontrolled 
study in 70 pediatric patients with HSP, on univariate analysis, renal involvement was 
significantly correlated with abdominal pain, gastrointestinal bleeding, and 3-month 
treatment with oral prednisone and/or 3 days of methylprednisolone pulse therapy 
(administration of high doses intravenously) (all, P < 0.005).23 Pulse therapy with 
cyclophosphamide during the first 3 months of HSP was indicated for patients with 
renal insufficiency or nephrotic syndrome who did not respond to pulse therapy with 
methylprednisolone. In patients with severe gastrointestinal involvement (ie, gastroin-
testinal infection) who did not respond to methylprednisolone pulse therapy, IVIg was 
administered 2 g/kg in a single dose. No significant differences in outcomes were found 
between the patients with or without HSPN. In a experimental study that includ- 
ed 15 adult patients with HSPN who received IVIg treatment (preparation content 
16.5%; 0.35 mL/kg every 15 days), overproduction of tumor necrosis factor and 
interleukin-6 was significantly reduced after 9 months (P < 0.01).28 Based on that 
experimental study, the efficacy of IVIg (2 g/kg, infused over 10–12 hours) in inhibit-
ing the progression of the disease was then tested in an unstructured case series.29 Thus, 
the efficacy of IVIg has not been confirmed in HSPN because the level of evidence 
remains low.
Coagulation Factors
One controlled clinical trial in 24 pediatric patients with moderate symptoms of 
HSP found that intravenous administration of factor XIII concentrate, 30 to 50 U/kg 
for 3 days, was associated with significant improvements in the severity of proteinuria 
and hematuria compared with a nontreated group.19 
Antioxidants
In an RCT in 38 children aged 3 to 15 years with HSPN, tocopherol 300 mg/d 
was administered for 6 to 17 weeks.17 Oxidative damage and worsening of the clini- 
cal course were observed despite significant increases in mean plasma vitamin E 
concentration.
In a case series of 5 children with biopsy-proven HSPN, treatment with an 
angiotensin-converting enzyme inhibitor ([ACEI]; enalapril) for hypertension and 
adjuvant treatment with fish oil 1 g BID, as an antioxidant, were associated with sig- 
nificantly decreased severity of proteinuria, decreased blood pressure, and stable serum cre- 
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Table I. Studies of treatment of moderate to severe Henoch-Schönlein purpura nephritis (HSPN) in children.
    Duration  Level of 
Study  Conventional Adjuvant of  Evidence*/ 
(Country) Design Treatment Treatment Follow-up Outcome Limitations
Chartapisak et al12 Meta-analysis of None Dipyridamole NA No significant Ib/small 
  (Australia) 4 RCTs that included  (4–5 mg/kg/d,  difference in sample size, 
 37 patients aged  2 trials) or   renal outcome poor study 
 <18 y with HSPN  acetylsalicylic   methodology 
   acid (5 mg/kg/d,    
   1 trial)
Erdogan et al17 RCT in patients aged None Tocopherol, 6–17 wk No significant Ib/small 
  (Turkey) 3–15 y with or without  300 mg/d until  difference in sample size 
 renal involvement   remission  renal outcome 
 (treatment group,  
 27 patients; control  
 group, 11)
Dixit et al18 Case series of Enalapril Fish oil 49 wk PU and blood V/small 
  (United States) 5 patients aged  (5–10 mg/d) (1 g BID) (21–83 wk) pressure sample size, 
 6–15 y with sample    decreased lack of 
 size, PU, and biopsy-    significantly controls 
 proven HSPN    (P < 0.05);   
     stable SCr 
     and GFR
(continued)
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Table I (continued).
    Duration  Level of 
Study  Conventional Adjuvant of  Evidence*/ 
(Country) Design Treatment Treatment Follow-up Outcome Limitations
Fukui et al19 Controlled clinical trial None FXIII 30–50 U/kg NA Severity of PU III/small 
  (Japan) in children with  IV × 3 d  and HU was sample size 
 HSPN and depressed    improved in the 
 FXIII concentration    treatment group 
 (treatment group,     compared with 
 10 patients; control    controls 
 group, 14)
Rostoker et al22 Prospective, nonrandomized None IVIg 2 g/kg/mo × NA Decreased PU, IV/small 
  (France) case series of patients  3 mo, then IMIg  decreased AI sample size 
 aged 0.6–19 y with moderate  0.35 mL/kg 
 PU and histology stage III,   twice per mo × 
 moderate AI, low CI, and   8 mo 
 normal renal function (IgAN   
 11 patients; HSP, 3)
de Almeida Retrospective,  (1) Oral (3) IVIg 2 g/kg 3 y No significant IV/lack of 
et al23 uncontrolled prednisone; in children who  difference controls 
  (Brazil) study in 70 patients  and/or pulse did not respond  between HSP 
 aged 2–14 y with MP; (2) CYCP × to MP  patients with  
 NS, renal failure, 3 mo if renal   or without   
 grade IV HSPN, and failure or NS   HSPN 
 isolated HU or PU did not respond 
 or both  to MP
RCT = randomized controlled trial; NA = not applicable; PU = proteinuria; SCr = serum creatinine; GFR = glomerular filtration rate; FXIII = factor XIII; IV = 
intravenous; HU = hematuria; AI = acuity index; CI = chronicity index; IgAN = immunoglobulin A nephropathy; HSP = Henoch-Schönlein purpura; 
IVIg = intravenous immunoglobulin; IMIg = intramuscular immunoglobulin; NS = nephrotic syndrome; CYCP = cyclophosphamide; MP = methylprednisolone.
* Levels of evidence classified in descending order as follows: Ia = evidence from meta-analysis of RCTs; Ib = evidence from ≥1 RCT; IIa = evidence 
from ≥1 controlled study without randomization; IIb = evidence from ≥1 other type of quasiexperimental study; III = evidence from nonexperimental 
descriptive studies, such as comparative, correlation, or case–control studies; and IV = evidence from expert committee reports or opinions, or from 
clinical experience of respected authorities or both.
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atinine concentration and glomerular filtration rate (P < 0.05).18 The limitations of 
that study, however, were the small sample size and the confounding antiproteinuric 
effect of the ACEI.20,30 
Anticoagulants
A systematic review of 3 RCTs in 37 children with HSPN reported no clear benefit 
of the use of dipyridamole (3–6 mg/kg/d for 8 weeks) and heparin (adjusted to main-
tain activated partial thromboplastin time [60 and 80 seconds] for 4 weeks) in treat-
ing HSPN, with limitations being the small number of studies, small sample size, and 
poor methodology of the studies.12 
Severe Henoch-Schönlein Purpura Nephritis 
Table II shows the adjuvant treatments of severe HSPN with crescent formations 
in children. Six studies matched the selection criteria.5,13,24–27 
Anticoagulants and Antiplatelets
The patients with severe HSP described in these articles had nephrotic syndrome, 
HSPN, rapidly progressive glomerulonephritis, and/or kidney failure. Histology of kid-
ney biopsies found a significant proportion with crescent formations (ISKDC grade 
IV–V21). These patients were at high risk for kidney failure despite aggressive treatment 
with cocktails that included adjuvant anticoagulants or antiplatelet agents such as 
heparin,24 warfarin,13,24,26 dipyridamole,5,13,24–27 and acetylsalicylic acid.27 Conventional 
adjuvant treatments included intravenous pulse methylprednisolone for 3 days and/or 
long-term oral prednisolone administration for 6 months.5,13,26,27 Intravenous steroids 
were used alone13 or in combination with (or to replace) cyclophosphamide,5 or compa-
rable steroid pulse therapy was used with cyclophosphamide26,27 and CSA.27 Oral ster-
oid therapy was used alone or in combination with cyclophosphamide.20,24,25
In a case series of 12 children aged 6 to 14 years with HSP, quadruple therapy with 
cyclophosphamide for 2 months, intravenous pulse methylprednisolone for 3 days, 
oral prednisone for 3 months, and adjuvant oral dipyridamole for 6 months, the glom-
erular filtration rate normalized in 11 patients, and 7 patients had complete remis-
sion.5 In a case series of 14 children followed up for a mean (SD) of 7.5 (0.9) years, 
combination treatment consisted of prednisone for 12 weeks, cyclophosphamide for 
8 weeks, and adjuvant intravenous heparin for 4 weeks, followed by warfarin 1 mg/d 
for 4 weeks  and dipyridamole for 8 weeks. The histologic abnormalities of the kidney 
significantly improved (P < 0.01).24 
In 2 retrospective studies, CSA was used for the treatment of severe HSPN in chil-
dren, either alone31 or in combination with steroids and adjuvant dipyridamole.27 In 
the latter—a retrospective, nonrandomized study in 82 children—prednisone or pulse 
methylprednisolone, cyclophosphamide, and CSA were administered; acetylsalicylic 
acid or dipyridamole was also administered as adjuvant therapy, although its dosing 
was not reported. After 6 months and long-term course, 35% and 62% of patients 
with nephritis had complete remission, respectively. In a case series of 13 patients with 
renal histology grade IIIb or IVb, prednisone was administered for 26 weeks, cyclo-
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Table II.  Studies of treatment of rapidly progressive glomerulonephritis or crescentic Henoch-Schönlein purpura nephritis (HSPN) 
with corticosteroid and immunosuppressive agents in children.
      Level of 
Study Study Conventional Adjuvant Duration of  Evidence*/ 
(Country) Design Treatment Treatment Follow-up Outcome Limitations
Oner et al5 Case series of (1) IV MP × 3 d (3) Dipyridamole Range, GFR normalization IV/lack of 
  (Turkey) 12 patients then prednisone × 5 mg/kg/d × 9–39 mo in 11 patients; controls 
 (mean [SD] age,  3 mo; (2) CYCP × 6 mo  complete 
 10.3 [2.3] y)  2 mo   remission in 
 with RPGN     7 patients
Kawasaki et al13 Retrospective, (1) Pulse MP × 3 d; (2) Pulse Mean (SD), Decreased AI, IV/lack of 
  (Japan) nonrandomized  then oral urokinase 9.7 (6.0) y recovery rates: controls 
 case series of prednisone × 6 mo 5000 U/kg/d  84% grade IIIb, 
 56 patients   (maximum,  62% grade IVb, 
 (mean [SD] age,  180,000 U) × 7 d;  25% grade Vb 
 8.6 [2.9] y)  (3) dipyridamole 
 with renal histology  5 mg/kg/d; 
 grade IIIb, IVb, Vb   (4) warfarin 
Iijima et al24 Case series of (1) Prednisone × (3) IV heparin × Mean (SD), Decreased IV/lack of 
  (Japan) 14 patients  12 wk; (2) CYCP × 4 wk; (4) warfarin 7.5 (0.9) y crescents/ controls 
 (aged 5–17.5 y) 8 wk 1 mg/d × 4 wk;  segmental 
 with renal histology  (5) dipyridamole  lesions, no ESRD 
 grade IV–V   3–6 mg/kg/d ×     
   8 wk
Tanaka et al25 Case series of (1) Prednisone × (3) Dipyridamole Mean (SD), Decreased AI, IV/small 
  (Japan) 9 patients 26 wk; (2) CYCP × 5 mg/kg/d up 78.3 (49.2) mo unchanged CI, sample 
 (aged 5.8–15.9 y) 8 wk to 300 mg/kg/d (range,  improved size 
 with renal histology   13–154 mo) histology stage 
 grade IIIb, IVb 
 (treatment group, 
 9 patients; control 
 group, 4)
(continued)
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Table II  (continued).
      Level of 
Study Study Conventional Adjuvant Duration of  Evidence*/ 
(Country) Design Treatment Treatment Follow-up Outcome Limitations
Kawasaki et al26 Retrospective, Group A: (1) IV MP × Group A and B: 24 mo AI decreased in III/short 
  (Japan) nonrandomized, 3 d, prednisone × (3) pulse urokinase  both groups; follow-up 
 controlled study  6 mo; group B: 5000 U/kg/d × 7 d;  CI decreased in 
 in 37 patients (1) IV MP × 3 d,  (4) dipyridamole   in group B only 
 (mean [SD] age, prednisone × 6 mo 5 mg/kg/d; 
 ~8.0 [3.0] y) (2) CYCP × 12 wk (5) warfarin × 24 mo
Mir et al27 Retrospective,  (1) Prednisone (3) Acetylsalicylic Median Recovery in 76% IV/lack of 
  (Turkey) nonrandomized  or pulse MP; acid or dipyridamole 52 mo (group 1) vs 53% controls 
 study in  (2) CYCP and CSA  (range, (group 2); long-term 
 82 patients    12–160 mo) recovery in 94.5% 
 (mean [SD] age,     (group 1) vs 
 9.3 [3.1] y)     62.2% (group 2) 
 with renal histology      
 grade I–V      
RPGN = rapidly progressive glomerulonephritis; IV = intravenous; MP = methylprednisolone; CYCP = cyclophosphamide; GFR = glomerular filtration 
rate; AI = acuity index; ESRD = end-stage renal disease; CI = chronicity index; CSA = cyclosporine A.
* Levels of evidence classified in descending order as follows: Ia = evidence from meta-analysis of randomized controlled trials (RCTs); Ib = evidence 
from ≥1 RCT; IIa = evidence from ≥1 controlled study without randomization; IIb = evidence from ≥1 other type of quasiexperimental study; III = evi-
dence from nonexperimental descriptive studies, such as comparative, correlation, or case–control studies; and IV = evidence from expert committee 
reports or opinions, or from clinical experience of respected authorities or both.
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phosphamide was administered for 8 weeks, and adjuvant therapy was dipyridamole 
5 mg/kg/d (maximum, 300 mg/d).25 At study end, the acuity index significantly de-
creased (P < 0.01), chronologic index remained unchanged, and renal histology grade 
significantly improved (P < 0.01).
Enzymes
In a controlled study in 37 children with severe HSPN, triple therapy with oral 
cyclophosphamide for 12 weeks, pulse methylprednisolone for 3 days, and IV pulse 
urokinase at 5000 U/kg/d (maximum, 180,000 U) for 7 consecutive days was effec-
tive.26 After 6 months, severity of proteinuria and mesangial IgA deposition were 
significantly reduced (P < 0.05 and P < 0.01, respectively).13,26 
DISCUSSION
The rationale behind adjuvant treatment is to increase the effectiveness of conventional 
therapy. Based on the literature search, no well-designed controlled trials of HSPN in 
children have been published. Moderate urinary abnormalities can be managed conser-
vatively with close monitoring of renal function. In cases of worsening renal function, 
some therapeutic options have been proposed or implemented based on clinical observa-
tions and clinical trials that were not well designed.10,12 Similar conclusions can be 
obtained from studies that used adjuvant treatments in children. Although the use of 
IVIg has been found to be effective in treating and protecting renal function in adults,32 
IVIg therapy might be considered with caution and mainly during the acute phase of 
HSP (recommendation C) in children with moderate urinary abnormalities who respond 
poorly to steroids. There have been no structured clinical investigations with regard to 
the use of factor XIII or fish oil (recommendations B and C, respectively). The antioxi-
dant vitamin E is not recommended.17 However, in children with severe HSPN, data do 
not support adjuvant treatment in addition to conventional treatments (recommenda-
tion C). Most of the studies included in the present review did not compare patients who 
did or did not receive adjuvant treatments, suggesting that conventional treatments (eg, 
pulse steroids, CSA, cyclophosphamide) are effective.13,24,26,27,31 
Although the beneficial effects of adjuvant treatments, such as dipyridamole or 
acetylsalicylic acid, combined with methylprednisolone and/or prednisone and CSA 
cannot be ignored, none of the studies reported high recommendation.12 Few studies, 
all unstructured, on the use of urokinase were found.15,26 They concluded that uroki-
nase was effective when administered with conventional immunosuppressants (recom-
mendation B). Observations were reported in retrospective case series, and the litera-
ture lacks reports of substantial clinical trials (recommendation C). Because the 
literature search did not identify any well-structured studies on the benefits from the 
use of antiplatelet agents or heparin in children with HSPN, the use of such therapy 
is not recommended at this time.
CONCLUSIONS
In this review, identified studies concerning the treatment of HSPN in children with 
adjuvant therapies were retrospective and recommendations were drawn from level IV 
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evidence. One RCT on the use of tocopherol as adjuvant treatment was identified; 
however, its clinical utility was not found. At present, there is no strong evidence 
supporting the use of adjuvant treatments for HSPN in children.
REFERENCES
 1. Andreoli SP. Renal manifestations of systemic diseases. Semin Nephrol. 1998;18:270–279.
 2. Coppo R, Gianoglio B, Porcellini MG, Maringhini S, for the Group of Renal Immunopathol-
ogy of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of 
the Italian Society of Nephrology. Frequency of renal diseases and clinical indications for renal 
biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). 
Nephrol Dial Transplant. 1998;13:293–297.
 3. Chang WL, Yang YH, Wang LC, et al. Renal manifestations in Henoch-Schönlein purpura: A 
10-year clinical study. Pediatr Nephrol. 2005;20:1269–1272.
 4. Bunchman TE, Mauer SM, Sibley RK, Vernier RL. Anaphylactoid purpura: Characteristics of 
16 patients who progressed to renal failure. Pediatr Nephrol. 1988;2:393–397.
 5. Oner A, Tinaztepe K, Erdogan O. The effect of triple therapy on rapidly progressive type of 
Henoch-Schönlein nephritis. Pediatr Nephrol. 1995;9:6–10.
 6. Sano H, Izumida M, Shimizu H, Ogawa Y. Risk factors of renal involvement and significant 
proteinuria in Henoch-Schönlein purpura. Eur J Pediatr. 2002;161:196–201.
 7. Dawod ST, Akl KF. Henoch-Schonlein syndrome in Qatar: The effects of steroid therapy and 
paucity of renal involvement. Ann Trop Paediatr. 1990;10:279–284.
 8. Roberti I, Reisman L, Churg J. Vasculitis in childhood. Pediatr Nephrol. 1993;7:479–489.
 9. Shin JI, Park JM, Shin YH, et al. Role of mesangial fibrinogen deposition in the pathogenesis 
of crescentic Henoch-Schonlein nephritis in children. J Clin Pathol. 2005;58:1147–1151.
10. Zaffanello M, Fanos V. Treatment-based literature of Henoch-Schönlein purpura nephritis in 
childhood [published online ahead of print December 9,2008]. Pediatr Nephrol.
11. Wyatt RJ, Hogg RJ. Evidence-based assessment of treatment options for children with IgA 
nephropathies. Pediatr Nephrol. 2001;16:156–167.
12. Chartapisak W, Opastiraku S, Willis NS, et al. Prevention and treatment of renal disease in 
Henoch-Schönlein purpura: A systematic review. Arch Dis Child. 2009;94:132–137.
13. Kawasaki Y, Suzuki J, Nozawa R, et al. Efficacy of methylprednisolone and urokinase pulse 
therapy for severe Henoch-Schönlein nephritis. Pediatrics. 2003;111:785–789.
14. Watanabe T, Takahashi S, Nakajo S, Hamasaki M. Pathological improvement of IgA nephropa-
thy and Henoch-Schönlein purpura nephritis with urokinase therapy. Acta Paediatr Jpn. 1996; 
38:622–628.
15. Kaku Y, Nohara K, Honda S. Renal involvement in Henoch-Schönlein purpura: A multivariate 
analysis of prognostic factors. Kidney Int. 1998;53:1755–1759.
16. Kaneko K, Fujii S, Shono T, et al. Diagnostic value of plasma factor XIII in Henoch-Schönlein 
purpura. Pediatr Nephrol. 2004;19:702–703. 
17. Erdogan O, Oner A, Aydin A, et al. Effect of vitamin E treatment on the oxidative damage 
occurring in Henoch-Schönlein purpura. Acta Paediatr. 2003;92:546–550.
18. Dixit MP, Dixit NM, Scott K. Managing Henoch-Schönlein purpura in children with fish oil 
and ACE inhibitor therapy. Nephrology (Carlton). 2004;9:381–386.
19. Fukui H, Kamitsuji H, Nagao T, et al, for the Japanese Pediatric Group. Clinical evaluation of 
a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Thromb Res. 
1989;56:667–675.
 265
M. Zaffanello et al.
20. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: Developing guidelines. 
BMJ. 1999;318:593–596.
21. Farine M, Poucell S, Geary DL, Baumal R. Prognostic significance of urinary findings and renal 
biopsies in children with Henoch-Schönlein nephritis. Clin Pediatr (Phila). 1986;25:257– 
259.
22. Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al. Immunomodulation with low-dose immuno-
globulins for moderate IgA nephropathy and Henoch-Schönlein purpura. Preliminary results 
of a prospective uncontrolled trial. Nephron. 1995;69:327–334.
23. de Almeida JL, Campos LM, Paim LB, et al. Renal involvement in Henoch-Schönlein purpura: 
A multivariate analysis of initial prognostic factors. J Pediatr (Rio J). 2007;83:259–266.
24. Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N. Multiple combined therapy for severe 
Henoch-Schönlein nephritis in children. Pediatr Nephrol. 1998;12:244–248.
25. Tanaka H, Suzuki K, Nakahata T, et al. Early treatment with oral immunosuppressants in se-
vere proteinuric purpura nephritis. Pediatr Nephrol. 2003;18:347–350.
26. Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy 
combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: A clinical 
and histopathological study. Nephrol Dial Transplant. 2004;19:858–864.
27. Mir S, Yavascan O, Mutlubas F, et al. Clinical outcome in children with Henoch-Schönlein 
nephritis. Pediatr Nephrol. 2007;22:64–70.
28. Rostoker G, Rymer JC, Bagnard G, et al. Imbalances in serum proinflammatory cytokines and 
their soluble receptors: A putative role in the progression of idiopathic IgA nephropathy 
(IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin 
therapy? Clin Exp Immunol. 1998;114:468–476.
29. Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis: Specula-
tion or evidence? Clin Rev Allergy Immunol. 2005;29:237–245.
30. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal 
protection in nondiabetic patients: The data of the meta-analyses. J Am Soc Nephrol. 2005;16 
(Suppl 1):S58–S63.
31. Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporine A for the treatment of severe 
Henoch-Schönlein glomerulonephritis. Pediatr Nephrol. 2003;18:1138–1142.
32. Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al. High-dose immunoglobulin therapy for se-
vere IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med. 1994;120:476–484.
Address correspondence to: Marco Zaffanello, MD, Department of 
Mother-Child and Biology-Genetics, University of Verona, Piazzale L. Scuro, 10, 
37134 Verona, Italy. E-mail: marco.zaffanello@univr.it
